We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Senate’s proposal adding $289 million to a compensation fund for individuals injured by a pandemic flu vaccine is insufficient and lacks the support from leadership in both houses of Congress to become law, the activist group Public Citizen says.
The Environmental Protection Agency (EPA) and Abbott Laboratories have agreed to settle alleged clean air violations at one of the company’s manufacturing plants.
House Democrats’ effort to clear the way for HHS to directly negotiate Medicare drug prices will likely fail as the House Rules Committee seems poised to block such a proposal, committee staffers say.
Pharmaceutical firm Eisai plans to build a manufacturing facility in Durham, N.C., to produce new cancer drugs, the Japanese-based company announced Feb. 27.
A key Senate committee that oversees the FDA hasn’t decided whether it will support the agency’s proposed industry user fee for reinspections of manufacturing facilities, questioning what it sees as a “unique” approach to increasing FDA funding.
The Bush administration has proposed an expanded tax credit for companies that manufacture medicines that target rare diseases, known as orphan drugs, in an effort to ramp up research into these illnesses.
A bipartisan group of House lawmakers used a Feb. 16 hearing on the FDA’s fiscal 2007 budget as an opportunity to blast the agency’s top official on several fronts, including delays in approving the Plan B emergency contraceptive and a growing backlog of generic drug reviews.
A key lawmaker has increased government oversight of drugmakers’ dealings with the Medicaid program through an expansion of the False Claims Act (FCA).
The Senate committee that oversees the FDA is uncertain whether it will support an agency proposal to institute new industry user fees, questioning what it sees as a “unique” approach to increasing FDA funding.